Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

NCT02144077 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

281

Enrollment

INDUSTRY

Sponsor class

Conditions

Basal Cell Carcinoma (BCC)

Interventions

DRUG: BF-200 ALA
DRUG: methyl-aminolevulinate

Sponsor

Biofrontera Bioscience GmbH

Collaborators

[object Object]